Skip to main content
Log in

Oral alendronate treatment for polyostotic fibrous dysplasia: a case report

  • Published:
Journal of Orthopaedic Science

Abstract

Recently, intravenous therapy with pamidronate has been reported to be effective for treating fibrous dysplasia. However, very little is known about the efficacy of oral alendronate for fibrous dysplasia. We describe a patient with polyostotic fibrous dysplasia, who had complained of persistent pain for more than 20 years, that was treated with oral alendronate alone. Follow-up examinations were at intervals of 3 months for 2 years. The pain, radiographic findings, and bone turnover, which was monitored using various markers, improved. No adverse side effect was noted. Oral alendronate is suggested to be a useful option in the treatment of polyostotic fibrous dysplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

About this article

Cite this article

Kitagawa, Y., Tamai, K. & Ito, H. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci 9, 521–525 (2004). https://doi.org/10.1007/s00776-004-0809-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00776-004-0809-0

Key words

Navigation